Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2026MedicinesOpen Access

Does Patient-Reported Olfactory Improvement Correlate with Quality of Life and Polyp Size Reduction in Patients with CRSwNP Treated with Dupilumab?

View Full Paper
Ask AI
Bookmark
Share

Authors

BHBrian Hernández-MartínMMMiriam del Carmen Marrero-RamosMCMaría Soledad Cabrera-Ramírez

Discussion

Loading...

Member takes

Overview

Retrospective study reveals patient-reported olfactory gains correlate with quality of life but not polyp reduction in severe CRSwNP, suggesting smell recovery involves mechanisms beyond polyp...

Key Points

  • To evaluate correlations between patient-reported olfactory improvement, quality-of-life gains, and endoscopic polyp reduction in patients with severe CRSwNP treated with dupilumab.
  • Retrospective single-center study evaluating 35 patients with severe, uncontrolled CRSwNP treated with dupilumab.
  • Assessed patient-reported olfaction (VAS-olfaction), quality of life (SNOT-22), and endoscopic polyp burden (NPS) at baseline, 6 months, and 12 months.
  • Evaluated longitudinal changes using the Wilcoxon signed-rank test and analyzed correlations using Spearman's rank correlation coefficient.
  • Dupilumab treatment produced significant improvements in VAS-olfaction, SNOT-22, and NPS at both 6 and 12 months compared to baseline.
  • VAS-olfaction improvements correlated significantly with total SNOT-22 score improvements at 6 months (p = 0.035) and 12 months (p = 0.024), though significance was lost when the smell/taste item was excluded.
  • No statistically significant correlation was observed between changes in patient-reported olfaction and reductions in Nasal Polyp Score.

Cite This Study

Hernández-Martín et al. (2026) studied this question.

synapsesocial.com/papers/6a8e9b21451774b83f3b3b8chttps://doi.org/10.3390/medicines13030026
View Full Paper
Ask AI
Bookmark
Share